January's top stories: Profectus Ebola trial, AstraZeneca-Incyte lung cancer drug
Profectus BioSciences began VesiculoVax-vectored vaccine trial, AstraZeneca and Incyte announced combination drug evaluation, SillaJen started Phase III trial for Pexa-Vec. Drugdevelopment-technology.com wraps-up the key headlines from January.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Cancer Vaccines | Ebola | Ebola Vaccine | Lung Cancer | Pharmaceuticals | Vaccines